Chimeric antigen receptor (CAR) T-cell therapy is a new type of immunotherapy that uses the body's own immune system to target cancer cells.| Myeloma Research News
Marisa Wexler is a senior science writer for Myeloma Research News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of myeloma topics.| Myeloma Research News
Median survival was 24.6 months, according to data from the 123 myeloma patients who took Elrexfio with the first group in MagnetisMM-3.| Myeloma Research News
The CAR T-cell therapy Carvykti controlled disease activity in most myeloma patients who hadn't fully responded to standard cell transplant.| Myeloma Research News